Adial Pharma Announces 1-for-25 Reverse Stock Split to Regain Nasdaq Compliance, Shares Plummet 20%

Adial Pharmaceuticals will implement a 1-for-25 reverse stock split to regain Nasdaq compliance. The move aims to restore the company's minimum bid price requirement, which expired on September 1, 2025. The split will reduce the number of outstanding shares from 27.8 million to 1.1 million. The company's lead drug product, AD04, is a serotonin-3 receptor antagonist for Alcohol Use Disorder treatment.